Your browser doesn't support javascript.
loading
A Phase I/II study of suberoylanilide hydroxamic acid (SAHA) in combination with trastuzumab (Herceptin) in patients with advanced metastatic and/or local chest wall recurrent HER2-amplified breast cancer: a trial of the ECOG-ACRIN Cancer Research Group (E1104).
Goldstein, Lori J; Zhao, Fengmin; Wang, Molin; Swaby, Ramona F; Sparano, Joseph A; Meropol, Neal J; Bhalla, Kapil N; Pellegrino, Christine M; Katherine Alpaugh, R; Falkson, Carla I; Klein, Paula; Sledge, George W.
Affiliation
  • Goldstein LJ; Fox Chase Cancer Center, Philadelphia, PA, USA. lori.goldstein@fccc.edu.
  • Zhao F; Dana Farber Cancer Institute - ECOG-ACRIN Biostatistics Center, Boston, MA, USA.
  • Wang M; Dana Farber Cancer Institute - ECOG-ACRIN Biostatistics Center, Boston, MA, USA.
  • Swaby RF; Fox Chase Cancer Center, Philadelphia, PA, USA.
  • Sparano JA; Merck Pharmaceuticals, North Wales, PA, USA.
  • Meropol NJ; West Chester Medical Center, Valhalla, NY, USA.
  • Bhalla KN; Fox Chase Cancer Center, Philadelphia, PA, USA.
  • Pellegrino CM; University Hospitals Case Medical Center, Cleveland, OH, USA.
  • Katherine Alpaugh R; MD Anderson Cancer Center, Houston, TX, USA.
  • Falkson CI; Georgia Regents University NCORP, Augusta, Georgia.
  • Klein P; West Chester Medical Center, Valhalla, NY, USA.
  • Sledge GW; Fox Chase Cancer Center, Philadelphia, PA, USA.
Breast Cancer Res Treat ; 165(2): 375-382, 2017 Sep.
Article in En | MEDLINE | ID: mdl-28623430
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Gene Amplification / Receptor, ErbB-2 Type of study: Prognostic_studies Limits: Adult / Aged / Female / Humans / Middle aged Language: En Journal: Breast Cancer Res Treat Year: 2017 Type: Article Affiliation country: United States
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Breast Neoplasms / Antineoplastic Combined Chemotherapy Protocols / Gene Amplification / Receptor, ErbB-2 Type of study: Prognostic_studies Limits: Adult / Aged / Female / Humans / Middle aged Language: En Journal: Breast Cancer Res Treat Year: 2017 Type: Article Affiliation country: United States